3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents

Michael Maeng, Hans-Henrik Tilsted, Lisette Okkels Jensen, Anne Kjer Kaltoft, Henning Kelbæk, Ulrik Abildgaard, Anton B Villadsen, Lars Romer Krusell, Jan Ravkilde, Knud Nørregaard Hansen, Evald Høj Christiansen, Jens Aarøe, Jan Skov Jensen, Steen Dalby Kristensen, Hans Erik Bøtker, Morten Madsen, Per Thayssen, Henrik Toft Sørensen, Leif Thuesen, Jens Flensted Lassen

    38 Citations (Scopus)

    Abstract

    This study sought to examine the 3-year clinical outcomes in patients treated with the Endeavor (Medtronic, Santa Rosa, California) zotarolimus-eluting stent (ZES) or the Cypher (Cordis, Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) in routine clinical practice.
    Original languageEnglish
    JournalCirculation. Cardiovascular interventions
    Volume5
    Issue number8
    Pages (from-to)812-8
    Number of pages7
    ISSN1941-7640
    DOIs
    Publication statusPublished - 2012

    Fingerprint

    Dive into the research topics of '3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents'. Together they form a unique fingerprint.

    Cite this